Interim data analysis of a phase 1 trial of chimeric antigen receptor-T cells (CAR-T) targeting the B-cell maturation antigen in heavily pretreated patients with multiple myeloma has identified an objective anti-tumor response, with limited toxicity.
Interim data analysis of a phase 1 trial of chimeric antigen receptor-T (CAR-T) cells targeting the B-cell maturation antigen (BCMA) in heavily pretreated patients with relapsed/refractory multiple myeloma has identified an objective anti-tumor response, with limited toxicity.
According to a press release by bluebird bio, which is developing the drug in collaboration with Celgene Corporation, the open-label trial is investigating the clinical impact of bb2121 anti-BCMA CAR-T cells, with phase 1 primary endpoints of incidence of adverse events and abnormal laboratory test results, including dose-limiting toxicities. Other data that the trial seeks to assess at this early stage include complete response, very good partial response, and partial response, as well as establish a recommended dose for future trials.
The study enrolled a total of 11 patients, who were dosed in 4 dose cohorts: 5.0 x 107, 15.0 x 107, 45.0 x 107, and 80 x 107 CAR-T cells. Patients had received, and failed, a median of 6 prior treatments; all had received a prior autologous stem cell transplant. Sixty-four percent of patients had received daratumumab or a CD38 antibody.
At the interim analysis, all 11 patients were eligible for safety evaluation, but only the first 9 enrolled were evaluable for efficacy, and underwent restaging. Prior to being infused with bb2121 anti-BCMA CAR-T cells produced from the patient’s own blood, patients received a conditioning regimen of cyclophosphamide and fuldarabine, similar to the trial by Juno Therapeutics, which was halted just last week following a report of additional patient deaths due to cerebral edema.
The overall response rate was a 100% in patients administered the dose of 15.0 x 107 and 45.0 x 107 (which was the highest dose in the 9 evaluable patients). Of the 3 patients given the lowest dose of 5.0 x 107 cells, a 50% reduction in disease symptoms was noted in at least 1 patient. In addition, a partial response was observed in the remaining 6 patients in the 2 other higher dose cohorts—importantly, 2 of the 6 patients were negative minimal residual disease.
David Davidson, MD, chief medical officer, bluebird bio, released a statement saying the company is pleased with the early results. “We are also encouraged by the safety profile to date, particularly the lack of severe cytokine release syndrome or neurotoxicity,” he added.
The trial results were presented today at the 28th EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium in Munich, Germany.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Lack of Mutations Associated With Favorable Prognosis in MPN-U
April 25th 2024While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for myeloproliferative neoplasm, unclassifiable (MPN-U).
Read More
What We’re Reading: FDA Approves UTI Antibiotic; Ozempic, Wegovy Price Investigation; US Births Fall
April 25th 2024The FDA recently approved an antibiotic for the treatment of urinary tract infections (UTIs) in women; a Senate committee recently launched an investigation into the prices of Novo Nordisk’s diabetes and weight loss drugs; US births fell last year, resuming a national slide after a previous increase during the pandemic.
Read More